{"id":"https://openalex.org/W4282941334","doi":"https://doi.org/10.1158/1538-7445.am2022-5534","title":"Abstract 5534: NTX-1088, a first-in-class anti-PVR mAb mediates DNAM1-dependent antitumor immunity","display_name":"Abstract 5534: NTX-1088, a first-in-class anti-PVR mAb mediates DNAM1-dependent antitumor immunity","publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282941334","doi":"https://doi.org/10.1158/1538-7445.am2022-5534"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-5534","doi":"https://doi.org/10.1158/1538-7445.am2022-5534","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-5534","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073088854","display_name":"Akram Obiedat","orcid":"https://orcid.org/0000-0002-7827-3370","observed_orcids":["https://orcid.org/0000-0002-7827-3370"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Akram Obiedat","raw_affiliation_strings":["1Nectin Therapeutics, Jerusalem, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Jerusalem, Israel;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074978291","display_name":"Anas Atieh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anas Atieh","raw_affiliation_strings":["1Nectin Therapeutics, Jerusalem, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Jerusalem, Israel;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007968346","display_name":"Guy Cinamon","orcid":"https://orcid.org/0000-0002-6988-1817","observed_orcids":["https://orcid.org/0000-0002-6988-1817"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guy Cinamon","raw_affiliation_strings":["1Nectin Therapeutics, Jerusalem, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Jerusalem, Israel;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082520283","display_name":"Keren Paz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keren Paz","raw_affiliation_strings":["1Nectin Therapeutics, Jerusalem, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Jerusalem, Israel;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044025083","display_name":"Paola Kucan Brilc","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I154347574","display_name":"University of Rijeka","ror":"https://ror.org/05r8dqr10","country_code":"HR","type":"education","lineage":["https://openalex.org/I154347574"]}],"countries":["HR"],"is_corresponding":false,"raw_author_name":"Paola Kucan Brilc","raw_affiliation_strings":["2University of Rijeka, Rijeka, Croatia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Rijeka, Rijeka, Croatia;","institution_ids":["https://openalex.org/I154347574"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077303927","display_name":"Lea Hir\u0161l","orcid":"https://orcid.org/0000-0003-1431-8581","observed_orcids":["https://orcid.org/0000-0003-1431-8581"]},"institutions":[{"id":"https://openalex.org/I154347574","display_name":"University of Rijeka","ror":"https://ror.org/05r8dqr10","country_code":"HR","type":"education","lineage":["https://openalex.org/I154347574"]}],"countries":["HR"],"is_corresponding":false,"raw_author_name":"Lea Hirsl","raw_affiliation_strings":["2University of Rijeka, Rijeka, Croatia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Rijeka, Rijeka, Croatia;","institution_ids":["https://openalex.org/I154347574"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064131245","display_name":"Tihana Lenac Rovi\u0161","orcid":"https://orcid.org/0000-0002-3299-1334","observed_orcids":["https://orcid.org/0000-0002-3299-1334"]},"institutions":[{"id":"https://openalex.org/I154347574","display_name":"University of Rijeka","ror":"https://ror.org/05r8dqr10","country_code":"HR","type":"education","lineage":["https://openalex.org/I154347574"]}],"countries":["HR"],"is_corresponding":false,"raw_author_name":"Tihana Lenac Rovi\u0161","raw_affiliation_strings":["2University of Rijeka, Rijeka, Croatia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Rijeka, Rijeka, Croatia;","institution_ids":["https://openalex.org/I154347574"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035583924","display_name":"Ofer Mandelboim","orcid":"https://orcid.org/0000-0002-9354-1855","observed_orcids":["https://orcid.org/0000-0002-9354-1855"]},"institutions":[{"id":"https://openalex.org/I197251160","display_name":"Hebrew University of Jerusalem","ror":"https://ror.org/03qxff017","country_code":"IL","type":"education","lineage":["https://openalex.org/I197251160"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Ofer Mandelboim","raw_affiliation_strings":["3Hebrew University, Jerusalem, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Hebrew University, Jerusalem, Israel","institution_ids":["https://openalex.org/I197251160"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038051461","display_name":"Stipan Jonji\u0107","orcid":"https://orcid.org/0000-0001-5003-3108","observed_orcids":["https://orcid.org/0000-0001-5003-3108"]},"institutions":[{"id":"https://openalex.org/I154347574","display_name":"University of Rijeka","ror":"https://ror.org/05r8dqr10","country_code":"HR","type":"education","lineage":["https://openalex.org/I154347574"]}],"countries":["HR"],"is_corresponding":false,"raw_author_name":"Stipan Jonjic","raw_affiliation_strings":["2University of Rijeka, Rijeka, Croatia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Rijeka, Rijeka, Croatia;","institution_ids":["https://openalex.org/I154347574"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5046611269","display_name":"Pini Tsukerman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pini Tsukerman","raw_affiliation_strings":["1Nectin Therapeutics, Jerusalem, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Jerusalem, Israel;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"5534","last_page":"5534"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tigit","display_name":"TIGIT","score":0.8029999732971191},{"id":"https://openalex.org/keywords/cd96","display_name":"CD96","score":0.9710000157356262},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.781000018119812},{"id":"https://openalex.org/keywords/anti-pd-1-combination-therapy","display_name":"anti-PD-1 combination therapy","score":0.8550000190734863},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.699999988079071},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.7540000081062317},{"id":"https://openalex.org/keywords/nk-cell-activation","display_name":"NK cell activation","score":0.7580000162124634},{"id":"https://openalex.org/keywords/cd8-t-cell-activation","display_name":"CD8+ T cell activation","score":0.878000020980835},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.3199999928474426}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.647566020488739},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.5900605916976929},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5825179219245911},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5542469024658203},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4419430196285248},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39411717653274536},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.36095374822616577},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.28430408239364624}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-5534","doi":"https://doi.org/10.1158/1538-7445.am2022-5534","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-5534","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3213939668","https://openalex.org/W4206777282","https://openalex.org/W4200217117","https://openalex.org/W4308377055","https://openalex.org/W4307906976","https://openalex.org/W4393093802","https://openalex.org/W4362545139","https://openalex.org/W7148649001","https://openalex.org/W7162525655","https://openalex.org/W4409411257"],"abstract_inverted_index":{"Abstract":[0],"Poliovirus":[1],"receptor":[2],"(PVR,":[3],"CD155),":[4],"expressed":[5],"on":[6,136],"the":[7,86,119,137,172,231,274,283,306,328,340,353,373,395,448],"surface":[8,138],"of":[9,27,50,88,131,139,174,202,206,239,276,321,343,359,366,376,447],"cancer":[10,158],"cells,":[11,200],"represents":[12],"a":[13,24,79,145,262,311,380,389,436],"resistance":[14,44],"mechanism":[15,358],"to":[16,45,53,75,247,273,292,332,394,398],"approved":[17],"immune":[18,28,140,164,187,296,348,385],"checkpoint":[19],"inhibitors":[20],"(ICIs).":[21],"It":[22],"is":[23,78,339,370,379],"key":[25],"regulator":[26],"activation,":[29,189],"that":[30,238,286,387],"modifies":[31],"function":[32],"through":[33],"multiple":[34],"mechanisms.":[35],"Increased":[36],"PVR":[37,51,58,100,123],"expression":[38,135],"levels":[39],"have":[40],"been":[41],"associated":[42],"with":[43,68,90,101,107,163,180,213,230,269,278],"anti-PD-(L)1":[46],"therapy,":[47],"while":[48],"loss":[49],"led":[52],"reduced":[54],"tumor":[55,207,313,329],"growth.":[56],"Targeting":[57],"using":[59],"mAbs":[60],"offers":[61],"an":[62,293],"intriguing":[63],"therapeutic":[64],"approach":[65],"for":[66,85,352,451],"patients":[67,89,399],"advanced":[69,92],"cancers,":[70],"who":[71],"are":[72],"not":[73],"responding":[74],"other":[76,336],"ICIs.NTX-1088":[77],"potent,":[80],"first-in-class,":[81],"anti-PVR":[82,438],"mAb,":[83,233],"developed":[84],"treatment":[87],"locally":[91],"and":[93,109,111,124,142,154,177,204,241,258,347,363,368,391,400],"metastatic":[94],"solid":[95],"tumors.":[96],"The":[97,235],"antibody":[98],"binds":[99],"high":[102],"affinity,":[103],"blocks":[104],"its":[105,134],"interactions":[106],"TIGIT":[108,240,367],"CD96,":[110],"preventing":[112],"their":[113,401],"inhibitory":[114],"signaling.":[115],"Moreover,":[116],"NTX-1088":[117,184,215,227,251,266,281,309,350],"block":[118],"critical":[120],"interaction":[121],"between":[122],"DNAM1":[125,289,345],"(CD226).":[126],"This":[127,338,378],"blockade":[128,365],"prevents":[129],"internalization":[130],"DNAM1,":[132],"restores":[133],"cells":[141,166,260,326],"results":[143],"in":[144,152,155,171,178,211,255,267,383],"robust":[146,312],"antitumor":[147,295,384,442],"activity.NTX-1088":[148],"was":[149,224,228,271,282],"thoroughly":[150],"investigated":[151],"vitro":[153],"vivo.":[156],"Various":[157],"cell":[159,188],"lines":[160],"were":[161],"co-cultured":[162],"effector":[165],"from":[167,195],"healthy":[168],"human":[169],"donors,":[170],"presence":[173],"NTX-1088,":[175,435],"alone":[176],"combination":[179,212,268,275],"anti-PD-1":[181],"mAb":[182,249,439],"(pembrolizumab).":[183],"significantly":[185,287,318],"increased":[186],"as":[190,261],"measured":[191,219],"by":[192,317,335,372],"IFN-gamma":[193],"release":[194],"activated":[196],"polyclonal":[197],"CD8+":[198,324],"T":[199,257,325],"induction":[201],"CD137":[203],"killing":[205],"cells.":[208],"When":[209,245],"tested":[210],"pembrolizumab,":[214,270],"further":[216],"improved":[217],"all":[218],"activation":[220,386],"parameters.":[221],"Synergistic":[222],"effect":[223,236],"obtained":[225],"when":[226],"combined":[229,243],"anti-CD112R":[232],"NTX-2R13.":[234],"surpassed":[237],"CD112R":[242],"inhibition.":[244],"compared":[246,331],"anti-TIGIT":[248],"(tiragolumab),":[250],"demonstrated":[252],"clear":[253],"superiority":[254],"activating":[256],"NK":[259],"single":[263],"agent.":[264],"Furthermore,":[265],"superior":[272],"pembrolizumab":[277],"tiragolumab.":[279],"Importantly,":[280],"only":[284],"intervention":[285],"restored":[288],"levels,":[290],"leading":[291],"enhanced":[294],"surveillance.":[297],"Numerous":[298],"humanized":[299],"murine":[300],"models,":[301,304],"including":[302],"pembrolizumab-insensitive":[303],"confirmed":[305],"above":[307],"observations;":[308],"exhibited":[310],"growth":[314],"inhibition,":[315],"accompanied":[316],"higher":[319],"prevalence":[320],"CD137+,":[322],"DNAM1+,":[323],"within":[327],"bed,":[330],"mice":[333],"treated":[334],"ICIs.":[337],"first":[341,354],"report":[342],"drug-induced":[344],"restoration":[346,375],"activation.":[349],"shows,":[351],"time,":[355],"exclusive":[356],"triple":[357],"action,":[360],"whereby":[361],"simultaneous":[362],"effective":[364],"CD96":[369],"complemented":[371],"efficient":[374],"DNAM1.":[377],"step":[381],"change":[382],"provides":[388],"remarkable":[390],"differentiated":[392],"addition":[393],"armamentarium":[396],"available":[397],"treating":[402],"oncologists.":[403],"An":[404],"IND":[405],"will":[406],"be":[407],"open":[408],"during":[409],"2Q2022.":[410],"Citation":[411],"Format:":[412],"Akram":[413],"Obiedat,":[414],"Anas":[415],"Atieh,":[416],"Guy":[417],"Cinamon,":[418],"Keren":[419],"Paz,":[420],"Paola":[421],"Kucan":[422],"Brilc,":[423],"Lea":[424],"Hirsl,":[425],"Tihana":[426],"Lenac":[427],"Rovi\u0161,":[428],"Ofer":[429],"Mandelboim,":[430],"Stipan":[431],"Jonjic,":[432],"Pini":[433],"Tsukerman.":[434],"first-in-class":[437],"mediates":[440],"DNAM1-dependent":[441],"immunity":[443],"[abstract].":[444],"In:":[445],"Proceedings":[446],"American":[449],"Association":[450],"Cancer":[452,463],"Research":[453],"Annual":[454],"Meeting":[455],"2022;":[456],"2022":[457],"Apr":[458],"8-13.":[459],"Philadelphia":[460],"(PA):":[461],"AACR;":[462],"Res":[464],"2022;82(12_Suppl):Abstract":[465],"nr":[466],"5534.":[467]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2022-06-16T00:00:00"}